Logo

PRE

Prenetics Global Limited

PRE

Prenetics Global Limited • NASDAQ
$14.55 ▲ 1.89% (+0.27)
Market Cap $192.66 M
52w High $17.99
52w Low $3.10
Dividend Yield 0%
P/E -4.05
Volume 60.48K
Outstanding Shares 13.24M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $23.555M ▲ $20.188M ▲ $-7.408M ▲ -31.45% ▲ $-0.53 ▲ $-6.724M ▲
Q2-2025 $17.68M ▲ $17.354M ▼ $-12.41M ▼ -70.192% ▼ $-0.94 ▼ $-10.889M ▲
Q1-2025 $17.312M ▲ $17.974M ▼ $-10.39M ▲ -60.016% ▲ $-0.8 ▲ $-11.004M ▲
Q4-2024 $10.488M ▲ $20.469M ▲ $-16.342M ▼ -155.812% ▼ $-1.29 ▼ $-24.89M ▼
Q3-2024 $7.778M $15.756M $-10.672M -137.211% $-0.84 $-10.931M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $23.726M ▼ $196.507M ▼ $35.305M ▼ $161.292M ▲
Q2-2025 $27.711M ▼ $199.106M ▼ $48.214M ▲ $150.982M ▼
Q1-2025 $58.528M ▼ $204.015M ▼ $42.899M ▲ $160.882M ▼
Q4-2024 $62.813M ▲ $213.575M ▼ $42.229M ▼ $170.389M ▼
Q3-2024 $42.832M $235.766M $55.67M $178.679M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-12.41M ▼ $0 $0 $0 $0 $0
Q1-2025 $-10.39M ▲ $0 $0 $0 $0 $0
Q4-2024 $-16.342M ▼ $0 $0 $0 $0 $0
Q3-2024 $-10.672M ▲ $0 $0 $0 $0 $0
Q2-2024 $-10.722M $0 $0 $0 $0 $0

Five-Year Company Overview

Income Statement

Income Statement Revenue has shrunk dramatically from the COVID-testing period and now sits at a very small base, suggesting the old business engine has largely wound down and the new lines are still early. The company has been loss-making for several years, with operating losses and net losses recurring as it invests in new products and markets. Profitability did not yet improve meaningfully after the pandemic boom faded, so the story is still very much about rebuilding and scaling a new business model rather than harvesting profits. Overall, the income statement points to a high-transition, high-investment phase with execution risk.

Balance Sheet

Balance Sheet The balance sheet shows a company with modest total assets, but importantly, it has moved from negative to positive equity, which indicates past balance sheet stress has been addressed to some extent. Cash remains meaningful but has come down from earlier levels, reflecting ongoing losses and investment in growth. Debt is very low, so financial leverage risk appears limited; instead, the main balance-sheet question is how long the existing cash and assets can support the current strategy. The additional use of Bitcoin as a treasury asset can add volatility and complexity to the balance sheet, which may amplify swings in reported financial position.

Cash Flow

Cash Flow Operating cash flow has recently turned negative again after a short period of being slightly positive, which means the core business is currently consuming cash rather than generating it. Free cash flow is also negative, though capital spending is quite light, so most cash burn seems tied to operating losses rather than heavy physical investment. This pattern is typical of an early-stage or pivoting company, but it does raise questions about the time available to reach scale and profitability before further funding might be needed. Cash management and the pace of burn will be key items to watch going forward.

Competitive Edge

Competitive Edge Prenetics is repositioning itself from a COVID-testing player to a broader health-tech and diagnostics company, competing in crowded but fast-growing markets. Its edge comes from a mix of proprietary painless blood collection technology, a celebrity-backed wellness brand (IM8), and exclusive access to advanced cancer detection science through Insighta. Partnerships with leading scientists and institutions provide scientific credibility that not all consumer-health competitors can match. However, it faces strong, well-funded rivals in at-home testing, supplements, and multi-cancer early detection, so market share is far from guaranteed and commercialization will be a long, competitive race.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of the strategy: Prenetics is investing in three main areas—consumer wellness (IM8), at-home diagnostics (Circle SnapShot), and multi-cancer early detection (Insighta). The company holds patents on its painless blood collection device and has exclusive access to FRAGMA-based cancer detection technology, which could be a meaningful scientific differentiator if clinical results are strong. Collaborations with high-profile scientists and universities deepen its R&D capabilities and expand its pipeline beyond any single product. The flip side is that these programs are early, require heavy ongoing R&D spending, and depend on successful trials, regulatory approvals, and real-world adoption, so outcomes remain uncertain.

Summary

Overall, PRE looks like a company in the middle of a major pivot: legacy COVID revenues have largely disappeared, and the new growth engines are still being built out. The business is currently loss-making and cash-flow negative, but it has a relatively clean balance sheet with low debt and a still-usable cash cushion, albeit one that is trending down. Its strategic opportunity lies in differentiated technologies, strong scientific partnerships, and a globally marketable wellness brand, all aimed at large and growing health markets. The main risks are execution, intense competition, regulatory and clinical uncertainty for its cancer programs, and the added financial volatility from its Bitcoin treasury approach. Success will depend on how quickly and effectively the company can turn its innovation pipeline into scalable, profitable businesses before financial flexibility tightens.

NEWS

November 25, 2025 · 8:49 AM UTC

Prenetics Announces Upcoming Conference Participation

Read more

November 24, 2025 · 7:30 AM UTC

Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million

Read more

November 20, 2025 · 8:57 PM UTC

H&M LAUNCHES NEW CONCEPT STORE IN BEVERLY HILLS, INTRODUCING H&M PRE-LOVED TO L.A.

Read more

November 14, 2025 · 8:35 AM UTC

Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth

Read more

November 10, 2025 · 7:24 AM UTC

Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

Read more